Jordana G Fein, Priya S Vakharia, A Paul Chous, Rutvi Desai, Fabiana Q Silva, Kimberly Reed, Alyson J Berliner, Robert Vitti, Charles C Wykoff
{"title":"在2期CANDELA研究中,afliberept 8 mg治疗nAMD的临床结果。","authors":"Jordana G Fein, Priya S Vakharia, A Paul Chous, Rutvi Desai, Fabiana Q Silva, Kimberly Reed, Alyson J Berliner, Robert Vitti, Charles C Wykoff","doi":"10.1016/j.oret.2025.03.023","DOIUrl":null,"url":null,"abstract":"<p><p>In this post hoc analysis of the CANDELA trial, eyes with neovascular age-related macular degeneration treated with aflibercept 8 mg achieved improved anatomic and visual outcomes, suggesting therapeutic benefit compared with aflibercept 2 mg.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Outcomes in nAMD with Aflibercept 8 mg in the Phase 2 CANDELA Study.\",\"authors\":\"Jordana G Fein, Priya S Vakharia, A Paul Chous, Rutvi Desai, Fabiana Q Silva, Kimberly Reed, Alyson J Berliner, Robert Vitti, Charles C Wykoff\",\"doi\":\"10.1016/j.oret.2025.03.023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this post hoc analysis of the CANDELA trial, eyes with neovascular age-related macular degeneration treated with aflibercept 8 mg achieved improved anatomic and visual outcomes, suggesting therapeutic benefit compared with aflibercept 2 mg.</p>\",\"PeriodicalId\":19501,\"journal\":{\"name\":\"Ophthalmology. Retina\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology. Retina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.oret.2025.03.023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oret.2025.03.023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Clinical Outcomes in nAMD with Aflibercept 8 mg in the Phase 2 CANDELA Study.
In this post hoc analysis of the CANDELA trial, eyes with neovascular age-related macular degeneration treated with aflibercept 8 mg achieved improved anatomic and visual outcomes, suggesting therapeutic benefit compared with aflibercept 2 mg.